Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report

被引：6
|
作者：
Montagna, E. [1 ]
Cancello, G. [1 ]
Torrisi, R. [1 ]
Rizzo, S. [2 ]
Scarano, E. [1 ]
Colleoni, M. [1 ]
机构：
[1] European Inst Oncol, Res Unit Med Senol, Dept Med, Milan, Italy
[2] European Inst Oncol, Div Diagnost Radiol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷 / 03期
关键词：
BEVACIZUMAB;
D O I：
10.1093/annonc/mdp563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：667 / U238
页数：2
相关论文
共 50 条
  • [1] Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Geyer, Charles E.
    Forster, John
    Lindquist, Deborah
    Chan, Stephen
    Romieu, C. Gilles
    Pienkowski, Tadeusz
    Jagiello-Gruszfeld, Agnieszka
    Crown, John
    Chan, Arlene
    Kaufman, Bella
    Skarlos, Dimosthenis
    Campone, Mario
    Davidson, Neville
    Berger, Mark
    Oliva, Cristina
    Rubin, Stephen D.
    Stein, Steven
    Cameron, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26): : 2733 - 2743
  • [2] Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
    Kaufman, Bella
    Stein, Steven
    Casey, Michelle A.
    Newstat, Beth O.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 61 - 65
  • [3] Efficacy and safety of the combination of lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    Aravantino-Fatorou, E.
    Christodoulou, C.
    Nikolakopoulou, A.
    Galani, E.
    Klouvas, G.
    Acholos, V.
    Karapanagiotidis, G.
    Batziou, E.
    Tsakalos, G.
    Skarlos, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Lapatinib can restore capecitabine sensitivity in HER2-positive breast cancer
    Cha, Y.
    Kim, H. P.
    Han, S. W.
    Oh, D. Y.
    Kim, J. H.
    Im, S. A.
    Bang, Y. J.
    Kim, T. Y.
    CANCER RESEARCH, 2009, 69 (02) : 249S - 250S
  • [5] LAPATINIB AND CAPECITABINE IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER WITH BRAIN METASTASES
    Dubianski, R.
    Brewczynska, E.
    Lemanska, I.
    Szombara, E.
    Nowecki, Z. I.
    ANNALS OF ONCOLOGY, 2014, 25
  • [6] Lapatinib in HER2-positive breast cancer
    Nelson, Roxanne
    LANCET ONCOLOGY, 2018, 19 (01): : 22 - 22
  • [7] Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Kang, Irene
    Spicer, Darcy V.
    Lu, Janice M.
    Groshen, Susan G.
    Tsao-Wei, Denice
    Garcia, Agustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Metronomic cyclophosphamide and capecitabine combined with lapatinib in heavily pretreated metastatic breast cancer (MBC) HER2-positive patients.
    Cagossi, Katia
    Lazzaretti, Maria Grazia
    Ferrari, Alessia
    Razzini, Giorgia
    Leporati, Meri
    Silvestri, Rosangela
    Iadanza, Manlio
    Iop, Aldo
    Artioli, Fabrizio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Retinal metastases treated with lapatinib (L) in a young HER2-positive breast cancer patient: Case report
    Sarti, M.
    Pagani, O.
    Bertoni, F.
    Longhi, S.
    Cafaro, C.
    Graffeo, R.
    Di Costanzo, F.
    Goldhirsch, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
    Hurvitz, Sara A.
    Kakkar, Reva
    BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 35 - 51
12345